Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in ReceivablesChange in Working CapitalDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Cash from Operations (2022 - 2025)

Historic Cash from Operations for Addex Therapeutics (ADXN) over the last 4 years, with Q2 2025 value amounting to $723.2 billion.

  • Addex Therapeutics' Cash from Operations fell 7019.73% to $723.2 billion in Q2 2025 from the same period last year, while for Jun 2025 it was -$10.6 billion, marking a year-over-year decrease of 10018.71%. This contributed to the annual value of -$6.1 million for FY2024, which is 3136.24% up from last year.
  • According to the latest figures from Q2 2025, Addex Therapeutics' Cash from Operations is $723.2 billion, which was down 7019.73% from -$665.9 billion recorded in Q1 2025.
  • Addex Therapeutics' Cash from Operations' 5-year high stood at $8307.9 billion during Q4 2023, with a 5-year trough of -$6175.0 billion in Q3 2024.
  • Its 4-year average for Cash from Operations is -$2.2 billion, with a median of -$4.2 million in 2022.
  • In the last 5 years, Addex Therapeutics' Cash from Operations surged by 26055001705.71% in 2023 and then tumbled by 9855441018.47% in 2024.
  • Over the past 4 years, Addex Therapeutics' Cash from Operations (Quarter) stood at -$3.2 million in 2022, then soared by 260550017.06% to $8307.9 billion in 2023, then dropped by 26.49% to $6107.1 billion in 2024, then plummeted by 88.16% to $723.2 billion in 2025.
  • Its last three reported values are $723.2 billion in Q2 2025, -$665.9 billion for Q1 2025, and $6107.1 billion during Q4 2024.